Usana Health Sciences chief commercial officer sells $153,387 in stock

Brent Neidig, the Chief Commercial Officer of USANA Health Sciences Inc . (NYSE:USNA), has recently sold shares of the company’s stock. According to a filing submitted to the Securities and Exchange Commission, Neidig disposed of a total of 4,743 shares on March 12, 2025. The shares were sold at an average price of $32.3397, with the transaction’s total value amounting to approximately $153,387. The sale occurred as USANA, currently valued at $620 million in market capitalization, trades at a modest P/E ratio of 14.4x. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.

The transaction was executed at prices ranging from $32.31 to $32.37 per share. Following this sale, Neidig no longer holds any shares in USANA Health Sciences directly. This move comes as the company continues to operate within the medicinal chemicals and botanical products sector, maintaining impressive gross profit margins of 81% and a strong financial health score according to InvestingPro, which offers 8 additional key insights about USANA’s financial position in its comprehensive Pro Research Report.

In other recent news, USANA Health Sciences reported its fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share (EPS) of $0.64, compared to the forecasted $0.49. The company also surpassed revenue expectations, reporting $214 million against the anticipated $208.84 million. Despite these positive results, USANA’s full-year earnings guidance for fiscal year 2025 disappointed investors, with a forecasted EPS range of $2.35-$3.00, falling short of the consensus estimate of $2.87. The projected revenue of $920-1000 million for FY2025 only bracketed the consensus estimate of $934.5 million.

USANA’s acquisition of Hiya Health, a children’s health market player, was noted as a strategic move to expand its market presence. The integration of Hiya Health is expected to contribute $145-$160 million to USANA’s net sales in 2025. Analysts from Sidoti and Company and D.A. Davidson expressed interest in USANA’s promotional strategies and growth plans, particularly in the U.S., Australia, and New Zealand markets, where the company saw significant sales increases.

The company’s growth strategy for 2025 includes launching over 20 new products and reformulations, along with implementing a new associate incentive program. USANA ended the year with $182 million in cash reserves and plans to increase this by $50-$60 million in 2025. The company acknowledged challenges in the Asia Pacific markets but remains optimistic about its growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.